GENOMICA Receives Authorization for the Commercialization of its Diagnostic Kits and Instruments in South Korea

Tuesday, November 14, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

MADRID, November 14, 2017 /PRNewswire/ --

GENOMICA, a leading molecular diagnostics company belonging to the PharmaMar

Group (MCE: PHM), has announced that it has received authorization in South Korea for commercializing CLART® in vitro diagnostic kits together with the autoclart® plus equipment by the competent healthcare authorities
(KFDA, for its acronym in English).

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

This authorization comes after the audit carried out to GENOMICA and after verifying that the company's facilities, the technical documentation and the quality system of the instruments and kits comply with the Korean Good Manufacturing Practices.

"Once we obtained the favorable dictum of the Korean authorities, we initiated the procedures to register the products and instruments. Today, we have sales authorization in South Korea, which is an important milestone for us as it is one of the most demanding accreditation bodies in the world and because it contributes to our expansion in Asia-Pacific ", explains Rosario Cospedal, General Director of GENOMICA.

GENOMICA has reached an agreement with the South Korean diagnostics company AGBIO Diagnostics for the distribution of kits and instruments in this country.

About GENOMICA 

GENOMIC is the first Spanish company in Molecular Diagnostics and highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability, automation and the highest quality standards. Our main objective is to maintain leadership in genomics applications within the Spanish market, and to extend internationally our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®

GENOMICA has developed diagnostic tests for human papillomavirus associated with cervical cancer, the diagnosis of viral respiratory diseases, multiple detection of human herpes and enteroviruses, as well as detection of gene regions associated to the determination of human therapy response factors, in particular in the Oncology field.

GENOMICA also provides analysis of DNA, Legal and Forensic Medicine, and Technology Transfer services.

About AGBIO Diagnostics 

AGBIO Diagnostics is the company in charge of distributing GENOMICA's kits and instruments in South Korea. This company, established in 1994, is specialized in genetic tests for infectious diseases diagnostics. It manufactures microarrays to detect Enteric Virus, drug resistance of Tubercular Bacillus and sexually transmitted diseases. Its corporate vision consist in relying on the potential of molecular diagnostics as a solid foundation for focusing their efforts on the development of innovative technology.

CONTACTS : Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store